Search
Now showing items 201-205 of 205
Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: A meta-analysis
(2007)
This study investigated the hypothesis that the insertion/deletion (4G/5G) polymorphism of the plasminogen activator inhibitor type-1 gene affects the risk for ischemic stroke, since results concerning this association ...
Weekly docetaxel in minimally pretreated cancer patients: A dose- escalation study focused on feasibility and cumulative toxicity of long-term administration
(1999)
Background: Docetaxel is an agent with impressive clinical activity but a rather poor profile of toxicity when given every three weeks. Therefore, optimisation of its clinical use is highly warranted. This is a dose- ...
Migration and HIV epidemic in Greece
(2005)
Background: Over the last decade, Greece has experienced a massive influx of migrants from countries in South Eastern/Central Europe, the Middle East, Asia and Africa. This study aimed to estimate the percentage and the ...
Rituximab in combination with CNOP chemotherapy in patients withn previously untreated indolent non-Hodgkin's lymphoma
(2003)
Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy. The purpose ...
Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome
(2009)
Locoregional recurrence is the most common failure pattern in patients with head and neck squamous cell carcinoma (HNSCC). We retrospectively identified 41 HNSCC patients with locoregional relapse and used kinetic reverse ...